Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.3%

3 terminated out of 29 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results79% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (10)
P 1 (8)
P 2 (7)
P 3 (1)
P 4 (1)

Trial Status

Completed11
Unknown9
Recruiting4
Terminated3
Not Yet Recruiting1
Suspended1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT05937620Not ApplicableRecruitingPrimary

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

NCT07341100Phase 2Not Yet RecruitingPrimary

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

NCT05891197Terminated

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05274451Phase 1Terminated

A Study to Investigate LYL797 in Adults With Solid Tumors

NCT02489903Phase 2Completed

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT06785077Not ApplicableRecruiting

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

NCT05001282Phase 1Terminated

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT06404671Not ApplicableRecruitingPrimary

Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

NCT05498597Phase 1Unknown

AMT-151 in Patients With Selected Advanced Solid Tumours

NCT02518256Not ApplicableCompletedPrimary

Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity

NCT02039388Not ApplicableCompletedPrimary

Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma

NCT04823871Not ApplicableCompletedPrimary

Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing

NCT02107937Phase 2Completed

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

NCT01631552Phase 1Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT02822157Phase 2UnknownPrimary

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

NCT03078400Phase 1UnknownPrimary

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

NCT03349463Phase 4Unknown

Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.

NCT02062697Not ApplicableCompletedPrimary

Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.

NCT02096783Not ApplicableCompleted

Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer

Scroll to load more

Research Network

Activity Timeline